Cardiff Oncology Inc reports results for the quarter ended September 30 - Earnings Summary

Cardiff Oncology Inc reported a quarterly adjusted loss of 17 cents per share for the quarter ended September 30, an improvement from a loss of 25 cents per share a year ago. Revenue fell 27.3% to $120,000, slightly above analyst expectations. The company incurred a total loss of $11.26 million. Despite a 9.2% rise in shares this quarter, they have lost 48.2% year-to-date. Analysts maintain a "buy" rating, with a median 12-month price target of $10.00, significantly above the current price of $2.25.